Journal article
A review of the oral direct thrombin inhibitor ximelagatran Not yet the end of the warfarin era…
Abstract
Ximelagatran is a direct thrombin inhibitor that offers numerous potential advantages compared with traditional anticoagulants. It is given orally, has a rapid onset of action, does not require laboratory monitoring, and is not associated with immune-mediated thrombocytopenia. Numerous phase III trials with ximelagatran focusing on deep vein thrombosis prophylaxis and treatment, stroke prevention in patients with atrial fibrillation, and …
Authors
Mohapatra R; Tran M; Gore JM; Spencer FA
Journal
American Heart Journal, Vol. 150, No. 1, pp. 19–26
Publisher
Elsevier
Publication Date
7 2005
DOI
10.1016/j.ahj.2005.02.012
ISSN
0002-8703